Paige M Glumac1, Colleen L Forster2, Hong Zhou1, Paari Murugan2, Shilpa Gupta3, Aaron M LeBeau1. 1. Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota. 2. Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota. 3. Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.
Abstract
BACKGROUND: The transmembrane glycoprotein CD133 is believed to be a marker of adult prostate stem cells and cancer stem/initiating cells. Investigating the role of CD133 in the normal biology of the prostate and in cancer is complicated by the lack of a sensitive and accurate antibody for its detection. Here, we describe the characterization of a unique antibody identified using human antibody phage display that can recognize CD133 in both formalin-fixed tissues and cell lines. METHODS: A human single-chain variable fragment (scFv) antibody phage display library possessing a diversity of 8 × 109 was screened against fully glycosylated recombinant CD133. A counter screen was performed against deglycosylated CD133 to select for clones that preferentially recognized a glycosylation-independent epitope. The lead scFv was analyzed by flow cytometry and cloned into a rabbit immunoglobulin scaffold for immunohistochemistry (IHC). RESULTS: The antibody designated HA10 was found to bind a glycosylation-independent epitope on the peptide backbone of CD133 with high affinity. As a reagent for flow cytometry, HA10 detected CD133 more accurately than a commonly used commercially available antibody. IHC analysis with HA10 documented the staining of basal cells and luminal cells in healthy prostate sections. Weak staining of luminal cells was observed in adenocarcinoma sections at a very low frequency. Examination of a LuCaP patient-derived xenograft tissue microarray found that only three of the LuCaP models were positive for CD133. The three CD133pos LuCaP models all originated from non-AR driven metastatic prostate cancer with neuroendocrine differentiation. Subsequent interrogation of liver biopsies from a patient who failed second-generation anti-androgen therapy found high levels of CD133 staining. The original transurethral resection of the prostate from that patient was, however, absent of CD133. CONCLUSIONS: We have developed a novel antibody that was able to detect CD133 by both IHC and flow cytometry. Using HA10 as an IHC reagent, we found that CD133 is a marker for a very rare cell type in both healthy prostate and adenocarcinoma sections. Our preliminary investigation also suggests that there may be an association between CD133 and non-AR driven prostate cancer with neuroendocrine differentiation.
BACKGROUND: The transmembrane glycoprotein CD133 is believed to be a marker of adult prostate stem cells and cancer stem/initiating cells. Investigating the role of CD133 in the normal biology of the prostate and in cancer is complicated by the lack of a sensitive and accurate antibody for its detection. Here, we describe the characterization of a unique antibody identified using human antibody phage display that can recognize CD133 in both formalin-fixed tissues and cell lines. METHODS: A human single-chain variable fragment (scFv) antibody phage display library possessing a diversity of 8 × 109 was screened against fully glycosylated recombinant CD133. A counter screen was performed against deglycosylated CD133 to select for clones that preferentially recognized a glycosylation-independent epitope. The lead scFv was analyzed by flow cytometry and cloned into a rabbit immunoglobulin scaffold for immunohistochemistry (IHC). RESULTS: The antibody designated HA10 was found to bind a glycosylation-independent epitope on the peptide backbone of CD133 with high affinity. As a reagent for flow cytometry, HA10 detected CD133 more accurately than a commonly used commercially available antibody. IHC analysis with HA10 documented the staining of basal cells and luminal cells in healthy prostate sections. Weak staining of luminal cells was observed in adenocarcinoma sections at a very low frequency. Examination of a LuCaP patient-derived xenograft tissue microarray found that only three of the LuCaP models were positive for CD133. The three CD133pos LuCaP models all originated from non-AR driven metastatic prostate cancer with neuroendocrine differentiation. Subsequent interrogation of liver biopsies from a patient who failed second-generation anti-androgen therapy found high levels of CD133 staining. The original transurethral resection of the prostate from that patient was, however, absent of CD133. CONCLUSIONS: We have developed a novel antibody that was able to detect CD133 by both IHC and flow cytometry. Using HA10 as an IHC reagent, we found that CD133 is a marker for a very rare cell type in both healthy prostate and adenocarcinoma sections. Our preliminary investigation also suggests that there may be an association between CD133 and non-AR driven prostate cancer with neuroendocrine differentiation.
Authors: Jason M D'Antonio; Donald J Vander Griend; Lizamma Antony; George Ndikuyeze; Susan L Dalrymple; Shahriar Koochekpour; John T Isaacs Journal: PLoS One Date: 2010-07-08 Impact factor: 3.240
Authors: Paige M Glumac; Joseph P Gallant; Mariya Shapovalova; Yingming Li; Paari Murugan; Shilpa Gupta; Ilsa M Coleman; Peter S Nelson; Scott M Dehm; Aaron M LeBeau Journal: Clin Cancer Res Date: 2019-11-15 Impact factor: 12.531
Authors: Marsela Jorgolli; Tanner Nevill; Aaron Winters; Irwin Chen; Su Chong; Fen-Fen Lin; Marissa Mock; Ching Chen; Kim Le; Christopher Tan; Philip Jess; Han Xu; Agi Hamburger; Jennitte Stevens; Trent Munro; Ming Wu; Philip Tagari; Les P Miranda Journal: Biotechnol Bioeng Date: 2019-06-24 Impact factor: 4.530
Authors: Heng Tang; Özlem Demir; Fredy Kurniawan; William L Brown; Ke Shi; Nicholas H Moeller; Michael A Carpenter; Christopher Belica; Kayo Orellana; Guocheng Du; Aaron M LeBeau; Rommie E Amaro; Reuben S Harris; Hideki Aihara Journal: Viruses Date: 2021-04-12 Impact factor: 5.048
Authors: Meixia Che; Aashi Chaturvedi; Sarah A Munro; Samuel P Pitzen; Alex Ling; Weijie Zhang; Josh Mentzer; Sheng-Yu Ku; Loredana Puca; Yanyun Zhu; Andries M Bergman; Tesa M Severson; Colleen Forster; Yuzhen Liu; Jacob Hildebrand; Mark Daniel; Ting-You Wang; Luke A Selth; Theresa Hickey; Amina Zoubeidi; Martin Gleave; Rohan Bareja; Andrea Sboner; Wayne Tilley; Jason S Carroll; Winston Tan; Manish Kohli; Rendong Yang; Andrew C Hsieh; Paari Murugan; Wilbert Zwart; Himisha Beltran; R Stephanie Huang; Scott M Dehm Journal: Nat Commun Date: 2021-11-04 Impact factor: 14.919